Save information for later
Sign Up

Learn About Methylmalonic Acidemia with Homocystinuria

What is the definition of Methylmalonic Acidemia with Homocystinuria?

Methylmalonic acidemia with homocystinuria is a disorder in which the body is unable to correctly process certain protein building blocks (amino acids), fat building blocks (fatty acids), and  cholesterol. The body is also unable to convert the amino acid homocysteine to another amino acid, methionine. Individuals with this disorder have a combination of features from two separate conditions, methylmalonic acidemia and homocystinuria. There are several forms of this combined condition, and the different forms have different genetic causes and signs and symptoms. The most common and best understood form, called cblC type (or cobalamin C disease), occurs in about 80 percent of affected individuals.

What are the causes of Methylmalonic Acidemia with Homocystinuria?

Methylmalonic acidemia with homocystinuria can be caused by variants (also known as mutations) in one of several genes, including MMACHC, MMADHC, LMBRD1, and ABCD4. Variants in these genes account for the different types of the disorder: cblC, cblD, cblF, and cblJ, respectively. Another type, called epi-cblC, is caused by variants in the PRDX1 gene, usually in combination with an MMACHC gene variant.

How prevalent is Methylmalonic Acidemia with Homocystinuria?

The most common form of the condition, methylmalonic acidemia with homocystinuria, cblC type, is estimated to affect 1 in 200,000 newborns worldwide. This form of the condition may be even more common in certain populations; some studies estimate that it occurs in 1 in 100,000 people in New York and 1 in 60,000 people in California.

Is Methylmalonic Acidemia with Homocystinuria an inherited disorder?

Methylmalonic acidemia with homocystinuria is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Who are the top Methylmalonic Acidemia with Homocystinuria Local Doctors?
Advanced in Methylmalonic Acidemia with Homocystinuria
Family Medicine
Advanced in Methylmalonic Acidemia with Homocystinuria
Family Medicine

Ballad Health Medical Associates

1021 W Oakland Ave, Ste 301, 
Johnson City, TN 
Languages Spoken:
English
Offers Telehealth

. Dr. Harman is rated as an Advanced provider by MediFind in the treatment of Methylmalonic Acidemia with Homocystinuria. His top areas of expertise are Vitamin B12 Deficiency Anemia, Folate Deficiency, Multiple Carboxylase Deficiency, and Subacute Combined Degeneration.

Experienced in Methylmalonic Acidemia with Homocystinuria
Family Medicine
Experienced in Methylmalonic Acidemia with Homocystinuria
Family Medicine

Summit Medical Group, PLLC

1225 E Weisgarber Rd, Suite 200, 
Knoxville, TN 
Languages Spoken:
English
Offers Telehealth

. Dr. Hensley is rated as an Experienced provider by MediFind in the treatment of Methylmalonic Acidemia with Homocystinuria. His top areas of expertise are Homocystinuria, Methylmalonic Acidemia with Homocystinuria, Type 2 Diabetes (T2D), and Inborn Amino Acid Metabolism Disorder.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Methylmalonic Acidemia with Homocystinuria
Hematology | Oncology
Experienced in Methylmalonic Acidemia with Homocystinuria
Hematology | Oncology

Tennessee Cancer Specialists

1301 Sunset Dr, Ste 3, 
Johnson City, TN 
Languages Spoken:
English
Offers Telehealth

. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Methylmalonic Acidemia with Homocystinuria. His top areas of expertise are Penile Cancer, Hemochromatosis, Non-Hodgkin Lymphoma, and Acute Mountain Sickness.

What are the latest Methylmalonic Acidemia with Homocystinuria Clinical Trials?
Clinical, Instrumental and Laboratory Data Collection of Subjects with Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases

Summary: General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: May 16, 2023
Published By: National Institutes of Health